Already registered? Need to register? Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Videos

PlayPCSK9 and Lp(a), a novel approach to a re-emergent cardiovascular risk factor

PCSK9 and Lp(a), a novel approach to a re-emergent cardiovascular risk factor

New disclosures show that inhibition of PCSK9 reduces Lp(a) cholesterol – an emerging risk factor for cardiovascular disease, according to US expert, Professor Henry Ginsberg.

read more »
PlayWeighing the cost versus benefit of PCSK9-targeted therapy

Weighing the cost versus benefit of PCSK9-targeted therapy

PCSK9 inhibitors are the most important advance in cholesterol lowering treatments since the discovery of statin drugs, says Spanish vascular disease researcher, Professor Lluís Masana.

read more »
PlayHigh cholesterol: an unmet need

High cholesterol: an unmet need

Health authorities are failing to recognise that most patients do not achieve the cholesterol levels needed to prevent cardiovascular disease. Professor Lluís Masana says this must become a public health priority.

read more »
PlayLooking ahead with PCSK9 Education & Research Forum

Looking ahead with PCSK9 Education & Research Forum

Researchers and clinicians are enthusiastically expanding their knowledge of important new discoveries in cholesterol lowering therapies with PCSK9 inhibitors. Co-editor, Professor Henry Ginsberg, looks to the future.

read more »
PlayWhat are the patient priorities for PCSK9 inhibitors?

What are the patient priorities for PCSK9 inhibitors?

The low density lipoprotein cholesterol (LDL-C) lowering potency of the new PCSK9 inhibitors, creates exciting opportunities to effectively lower lipids in high risk patients, including those with familial hypercholesterolaemia (FH) for the first time. Professor Henry Ginsberg discusses the clinical potential of these new therapies.

read more »
PlayDoes PCSK9 inhibition impact atherosclerosis?

Does PCSK9 inhibition impact atherosclerosis?

Research shows that progression of atherosclerosis – narrowing of the coronaries due to high density lipoprotein cholesterol (HDL-C) – may be reduced if statins are combined with new PCSK9 inhibitors. This could prevent heart attacks according to one of the trialists, Professor Steve Nicholls from…

read more »
PlayLoss of function mutations in PCSK9: the trigger for therapeutic development

Loss of function mutations in PCSK9: the trigger for therapeutic development

Studies of mutations of PCSK9 function have identified a new therapeutic target for reducing very high levels of low density lipoprotein cholesterol (LDL-C). Professor Anne Tybjaerg-Hansen describes this opportunity.

read more »
PlayDoes PCSK9 have effects beyond the liver and if so, what is the evidence?

Does PCSK9 have effects beyond the liver and if so, what is the evidence?

Laboratory research conducted in France shows that PCSK9 may have effects beyond its primary action in the liver, where its inhibition significantly lowers low density lipoprotein cholesterol (LDL-C). These studies also provide reassuring data about the probable safety of these new therapies, Professor Bertrand Cariou…

read more »
PlayFamilial hypercholesterolaemia: putting the patient first

Familial hypercholesterolaemia: putting the patient first

Patients and their families must be proactively involved in the identification and treatment of people with familial hypercholesterolaemia (FH) – a group whose severely raised low density lipoprotein cholesterol (LDL-C) puts them at a very high risk of premature death. Founder and CEO of the…

read more »
PlayOverlap between HoFH and severe FH and implications for evolocumab

Overlap between HoFH and severe FH and implications for evolocumab

The implications of the overlap between homozygous hypercholesterolaemia and severe familial hypercholesterolaemia (FH) – two genetic disorders characterised by very high levels of low density lipoprotein cholesterol (LDL-C) – should be considered when selecting treatment. Professor Frederick Raal discusses the issue.

read more »
PlayImplications from TESLA for FH management

Implications from TESLA for FH management

The investigational PCSK9 inhibitor evolocumab, promises to be an important new treatment for a rare but serious genetic disorder, homozygous familial hypercholesterolaemia, according to one of the investigators in the TESLA study, Professor Frederick Raal.

read more »
PlayImplications from TESLA and early TAUSSIG studies with evolocumab

Implications from TESLA and early TAUSSIG studies with evolocumab

Results of clinical trials of the investigational therapy – evolocumab, a PCSK9 inhibitor will potentially change care of patients at a high risk of cardiovascular disease (heart attacks), by reducing their very high low density lipoprotein cholesterol (LDL-C) levels.

read more »
PlayThe role of PCSK9 inhibitors in FH

The role of PCSK9 inhibitors in FH

The low density lipoprotein cholesterol (LDL-C) lowering effects of evolocumab, a new PCSK9 inhibitor, in patients with familial hypercholesterolaemia (FH) are very encouraging, Dr Dirk Blom, University of Cape Town says. This will be very important in countries such as South Africa.

read more »
PlayWhat are the gaps in knowledge about the PCSK9 inhibitors

What are the gaps in knowledge about the PCSK9 inhibitors

Large clinical studies of innovative monoclonal antibodies targeting PCSK9 to significantly reduce low density lipoprotein cholesterol (LDL-C). Professor Evan Stein predicts the therapies will be on the market in 2015.

read more »
PlayDo the PCSK9 monoclonal antibodies have neurocognitive effects

Do the PCSK9 monoclonal antibodies have neurocognitive effects

There is reassuring evidence of the neurocognitive safety of the monoclonal antibodies developed to reduce low density lipoprotein cholesterol (LDL-C) by targeting PCSK9, Professor Frederick Raal discusses this topic.

read more »
PlayWill the PCSK9 monoclonal antibodies replace other lipid lowering treatment used with statins

Will the PCSK9 monoclonal antibodies replace other lipid lowering treatment used with statins

Where will the new PCSK9 inhibitors fit into the treatment of people whose raised low density lipoprotein cholesterol (LDL-C) puts them at high risk of cardiovascular disease? Leading researcher, Professor Frederick Raal discusses this important question.

read more »
PlayNew ACC/AHA guidelines for cholesterol management: View from the Editors

New ACC/AHA guidelines for cholesterol management: View from the Editors

Should low density lipoprotein cholesterol (LDL-C) targets have been dropped from guidelines? Probably not argues Professor Henry Ginsberg, Co-editor of the PCSK9 Forum.

read more »
PlayLDL-C: how low should clinicians aim for?

LDL-C: how low should clinicians aim for?

Trials with monoclonal antibodies – PCSK9 inhibitors – will answer the question of how far should low density lipoprotein cholesterol (LDL-C) be reduced?

read more »
PlayLowering LDL-C: How low and for how long?

Lowering LDL-C: How low and for how long?

Treatment to reduce low density lipoprotein cholesterol (LDL-C) should be started in teenage years in people with very high risk of cardiovascular death or events e.g. heart attacks. There is substantial evidence showing significant benefits if LDL-C is reduced by about 50%, Professor Evan Stein…

read more »
PlayWhy is it critical to target children with FH?

Why is it critical to target children with FH?

Familial hypercholesterolaemia (FH) is the most common genetic disorder in the world. People with FH have high levels of low density lipoprotein cholesterol (LDL-C) resulting in a high risk of premature and sudden death. Now early diagnosis and treatment can save lives, says Dr Albert…

read more »